Savara Pharmaceuticals is a clinical-stage biopharmaceutical company dedicated to developing innovative treatments for rare respiratory diseases, particularly focusing on autoimmune pulmonary alveolar proteinosis (aPAP). Their lead product candidate, molgramostim, is an inhaled granulocyte-macrophage colony-stimulating factor (GM-CSF) currently in Phase 3 clinical development. This therapy aims to address the underlying disruption of GM-CSF signaling that is critical for pulmonary alveolar macrophages to effectively clear surfactant, which accumulates in patients with aPAP. Clinical trials have demonstrated that inhaled molgramostim can significantly improve pulmonary gas exchange and enhance the quality of life for patients suffering from this rare condition.

The company’s research is supported by a robust Clinical Advisory Board comprising experts in interstitial lung diseases and pulmonary medicine. These professionals are involved in various aspects of clinical research and trials, contributing to the understanding and treatment of aPAP and related conditions. Their collective expertise encompasses the development of novel therapeutic targets and diagnostic tests, as well as participation in international clinical trials aimed at improving patient outcomes. Through these efforts, Savara Pharmaceuticals is committed to advancing the science of rare respiratory diseases and providing effective treatment options for affected individuals.

United States

Savara is a clinical stage biopharmaceutical company focused on rare respiratory diseases. Our lead program, molgramostim nebulizer solution, is an inhaled granulocyte-macrophage colony-stimulating factor (GM-CSF) in Phase 3 development for autoimmune pulmonary alveolar proteinosis (aPAP). Our management team has significant experience in rare respiratory diseases and pulmonary medicine, identifying unmet needs, and effectively advancing product candidates to approval and commercialization. 

More information can be found at www.savarapharma.com. More information on the Phase 3 IMPALA-2 clinical trial in aPAP can be found at www.impala2.com

Savara Pharmaceuticals

Company Details